{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:08:16Z","timestamp":1791227296821,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02202-3","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:53:35Z","timestamp":1780664015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Jiajia","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"1","key":"2202_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.17925\/ee.2023.19.1.7","volume":"19","author":"M Li","year":"2023","unstructured":"Li M, Jeeyavudeen MS, Arunagirinathan G, Pappachan J. Is Type 2 Diabetes Mellitus a Behavioural Disorder? An Evidence Review for Type 2 Diabetes Mellitus Prevention and Remission through Lifestyle Modification. touchREV Endocrinol. 2023;19(1):7\u201315. https:\/\/doi.org\/10.17925\/ee.2023.19.1.7.","journal-title":"touchREV Endocrinol"},{"issue":"7","key":"2202_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jcjd.2023.06.002","volume":"47","author":"T Gignac","year":"2023","unstructured":"Gignac T, Tr\u00e9panier G, Paquet V, Ferland S, Carreau AM. Glycated Hemoglobin Is Suboptimal for the Screening of Prediabetes and Type 2 Diabetes in Adults With Nonalcoholic Fatty Liver Disease. Can J Diabetes. 2023;47(7):603\u201310. https:\/\/doi.org\/10.1016\/j.jcjd.2023.06.002.","journal-title":"Can J Diabetes"},{"issue":"6","key":"2202_CR3","doi-asserted-by":"publisher","first-page":"Itc81","DOI":"10.7326\/aitc202306200","volume":"176","author":"M Arvanitis","year":"2023","unstructured":"Arvanitis M, Lowenstein CJ, Dyslipidemia. Ann Intern Med. 2023;176(6):Itc81\u201396. https:\/\/doi.org\/10.7326\/aitc202306200.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2202_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/00132577-200512000-00018","volume":"4","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol. 2005;4(4):198\u2013203. https:\/\/doi.org\/10.1097\/00132577-200512000-00018.","journal-title":"Crit Pathw Cardiol"},{"issue":"7","key":"2202_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11883-023-01114-1","volume":"25","author":"JP Zachariah","year":"2023","unstructured":"Zachariah JP, Double-Trouble. Atherosclerotic Risk Factors and Congenital Heart Disease. Curr Atheroscler Rep. 2023;25(7):417\u201326. https:\/\/doi.org\/10.1007\/s11883-023-01114-1.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"2202_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000531432","volume":"148","author":"JZ Li","year":"2023","unstructured":"Li JZ, Li YR. Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research. Cardiology. 2023;148(4):374\u201384. https:\/\/doi.org\/10.1159\/000531432.","journal-title":"Cardiology"},{"issue":"3","key":"2202_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5603\/EP.a2023.0036","volume":"74","author":"H Dai","year":"2023","unstructured":"Dai H, Zhu Y, Chen Z, Yan R, Liu J, He Z, et al. Impact of alirocumab\/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials. Endokrynol Pol. 2023;74(3):234\u201342. https:\/\/doi.org\/10.5603\/EP.a2023.0036.","journal-title":"Endokrynol Pol"},{"issue":"2","key":"2202_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/circresaha.118.312782","volume":"124","author":"NC Ward","year":"2019","unstructured":"Ward NC, Watts GF, Eckel RH, Statin Toxicity. Circ Res. 2019;124(2):328\u2013. https:\/\/doi.org\/10.1161\/circresaha.118.312782. \u200950.","journal-title":"Circ Res"},{"issue":"2","key":"2202_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jama.2023.9696","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. Jama. 2023;330(2):131\u201340. https:\/\/doi.org\/10.1001\/jama.2023.9696.","journal-title":"Jama"},{"issue":"11","key":"2202_CR10","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.14309\/ajg.0000000000001956","volume":"117","author":"KV Kowdley","year":"2022","unstructured":"Kowdley KV, Forman L, Eksteen B, Gunn N, Sundaram V, Landis C, et al. A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis. Am J Gastroenterol. 2022;117(11):1805\u201315. https:\/\/doi.org\/10.14309\/ajg.0000000000001956.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"2202_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm1135","volume":"10","author":"W Kong","year":"2004","unstructured":"Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344\u201351. https:\/\/doi.org\/10.1038\/nm1135.","journal-title":"Nat Med"},{"key":"2202_CR12","doi-asserted-by":"publisher","first-page":"107496","DOI":"10.1016\/j.pharmthera.2020.107496","volume":"209","author":"WJ Kong","year":"2020","unstructured":"Kong WJ, Vernieri C, Foiani M, Jiang JD. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. Pharmacol Ther. 2020;209:107496. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107496.","journal-title":"Pharmacol Ther"},{"key":"2202_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365529409103618","volume":"204","author":"AF Hofmann","year":"1994","unstructured":"Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl. 1994;204:1\u201315. https:\/\/doi.org\/10.3109\/00365529409103618.","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"2","key":"2202_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/ijms27020747","volume":"27","author":"X Tian","year":"2026","unstructured":"Tian X, Chen Q, He Y, Cheng Y, Zhao M, Li Y, et al. Berberine: A Negentropic Modulator for Multi-System Coordination. Int J Mol Sci. 2026;27(2):747. https:\/\/doi.org\/10.3390\/ijms27020747.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2202_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/s2468-1253(19)30343-7","volume":"5","author":"RA Shah","year":"2020","unstructured":"Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol. 2020;5(3):306\u2013. https:\/\/doi.org\/10.1016\/s2468-1253(19)30343-7. \u200915.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2202_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/endrev\/bnab037","volume":"43","author":"AJ Berberich","year":"2022","unstructured":"Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev. 2022;43(4):611\u2013. https:\/\/doi.org\/10.1210\/endrev\/bnab037. \u200953.","journal-title":"Endocr Rev"},{"key":"2202_CR17","doi-asserted-by":"publisher","first-page":"653887","DOI":"10.3389\/fphar.2021.653887","volume":"12","author":"Y Ye","year":"2021","unstructured":"Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, Chen Q. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021;12:653887. https:\/\/doi.org\/10.3389\/fphar.2021.653887.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2202_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12944-020-01406-4","volume":"19","author":"AM Di Bisceglie","year":"2020","unstructured":"Di Bisceglie AM, Watts GF, Lavin P, Yu M, Bai R, Liu L. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids Health Dis. 2020;19(1):239. https:\/\/doi.org\/10.1186\/s12944-020-01406-4.","journal-title":"Lipids Health Dis"},{"key":"2202_CR19","doi-asserted-by":"publisher","first-page":"289264","DOI":"10.1155\/2014\/289264","volume":"2014","author":"Z Li","year":"2014","unstructured":"Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med. 2014;2014:289264. https:\/\/doi.org\/10.1155\/2014\/289264.","journal-title":"Evid Based Complement Alternat Med"},{"key":"2202_CR20","doi-asserted-by":"publisher","first-page":"174590","DOI":"10.1016\/j.ejphar.2021.174590","volume":"913","author":"N Hedayati","year":"2021","unstructured":"Hedayati N, Oskouei Z, Tabeshpour J, Naeini MB. Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review. Eur J Pharmacol. 2021;913:174590. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174590.","journal-title":"Eur J Pharmacol"},{"key":"2202_CR21","doi-asserted-by":"publisher","first-page":"762654","DOI":"10.3389\/fphar.2021.762654","volume":"12","author":"X Ai","year":"2021","unstructured":"Ai X, Yu P, Peng L, Luo L, Liu J, Li S, et al. Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases. Front Pharmacol. 2021;12:762654. https:\/\/doi.org\/10.3389\/fphar.2021.762654.","journal-title":"Front Pharmacol"},{"key":"2202_CR22","doi-asserted-by":"publisher","first-page":"106481","DOI":"10.1016\/j.phrs.2022.106481","volume":"185","author":"S Hu","year":"2022","unstructured":"Hu S, Wang J, Liu E, Zhang X, Xiang J, Li W, et al. Protective effect of berberine in diabetic nephropathy: A systematic review and meta-analysis revealing the mechanism of action. Pharmacol Res. 2022;185:106481. https:\/\/doi.org\/10.1016\/j.phrs.2022.106481.","journal-title":"Pharmacol Res"},{"key":"2202_CR23","doi-asserted-by":"publisher","first-page":"709629","DOI":"10.3389\/fphar.2021.709629","volume":"12","author":"S Yang","year":"2021","unstructured":"Yang S, Li D, Yu Z, Li Y, Wu M. Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota. Front Pharmacol. 2021;12:709629. https:\/\/doi.org\/10.3389\/fphar.2021.709629.","journal-title":"Front Pharmacol"},{"key":"2202_CR24","doi-asserted-by":"publisher","unstructured":"Reddi KK, Li H, Li W, Tetali SD, Berberine A, Phytoalkaloid. Inhibits Inflammatory Response Induced by LPS through NF-Kappa\u03b2 Pathway: Possible Involvement of the IKK\u03b1. Molecules. 2021;26(16). https:\/\/doi.org\/10.3390\/molecules26164733.","DOI":"10.3390\/molecules26164733"},{"issue":"52","key":"2202_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.4103\/pm.pm_584_16","volume":"13","author":"D Li","year":"2017","unstructured":"Li D, Zheng J, Hu Y, Hou H, Hao S, Liu N, Wang Y. Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats. Pharmacogn Mag. 2017;13(52):677\u201382. https:\/\/doi.org\/10.4103\/pm.pm_584_16.","journal-title":"Pharmacogn Mag"},{"issue":"2","key":"2202_CR26","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.3350\/cmh.2025.0868","volume":"32","author":"Z Lei","year":"2026","unstructured":"Lei Z. Surrogates without substance? Questioning the evidence for histologic improvement with HTD1801: Letter to the editor on HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clin Mol Hepatol. 2026;32(2):e158\u201360. https:\/\/doi.org\/10.3350\/cmh.2025.0868.","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"2202_CR27","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/cid\/ciaa623","volume":"71","author":"J Fan","year":"2020","unstructured":"Fan J, Zhang X, Liu J, Yang Y, Zheng N, Liu Q, et al. Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019. Clin Infect Dis. 2020;71(12):3232\u20136. https:\/\/doi.org\/10.1093\/cid\/ciaa623.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2202_CR28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/cpdd.625","volume":"8","author":"SY Kim","year":"2019","unstructured":"Kim SY, Jeon JY, Park SJ, Kim MG. Pharmacokinetics of a Lobeglitazone\/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5\/1000\u00a0mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects. Clin Pharmacol Drug Dev. 2019;8(5):576\u201384. https:\/\/doi.org\/10.1002\/cpdd.625.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"2202_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-023-01841-4","volume":"83","author":"JE Blais","year":"2023","unstructured":"Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023;83(5):403\u201327. https:\/\/doi.org\/10.1007\/s40265-023-01841-4.","journal-title":"Drugs"},{"key":"2202_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","volume":"161","author":"J Lan","year":"2015","unstructured":"Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69\u201381. https:\/\/doi.org\/10.1016\/j.jep.2014.09.049.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"2202_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cmet.2017.10.009","volume":"27","author":"SC Lin","year":"2018","unstructured":"Lin SC, Hardie DG. AMPK: Sensing Glucose as well as Cellular Energy Status. Cell Metab. 2018;27(2):299\u2013313. https:\/\/doi.org\/10.1016\/j.cmet.2017.10.009.","journal-title":"Cell Metab"},{"issue":"3","key":"2202_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/1871530315666150316124019","volume":"15","author":"Y Saisho","year":"2015","unstructured":"Saisho Y. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocr. Metab Immune Disord Drug Targets. 2015;15(3):196\u2013205. https:\/\/doi.org\/10.2174\/1871530315666150316124019.","journal-title":"Metab Immune Disord Drug Targets"},{"issue":"1","key":"2202_CR33","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","volume":"12","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021;12(1):5503. https:\/\/doi.org\/10.1038\/s41467-021-25701-5.","journal-title":"Nat Commun"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02202-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02202-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02202-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:02:43Z","timestamp":1786453363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02202-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2202"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02202-3","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was prepared per the principles of the Declaration of Helsinki and approved by the Institutional Review Board of the First Hospital of Jilin University (21Y345-001). All recruited patients provided written informed consent before participating in any study-related procedures.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"171"}}